FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Czock

Research Profile

Disorders

Procedures

Chemicals & Drugs

Anatomy

Kidneys

Concepts & Ideas

Physiology

Phenomena

Metabolic Clearance Rate

Co-author Network

Publications

TOP 3
Heiko Billing; David Czock; Thomas Giese; Stefan Meuer; Claudia Sommerer; Martin Zeier; Burkhard Tönshoff
Increased cyclosporin a sensitivity in vivo in pediatric renal transplant recipients compared with adults.
David Czock; Frieder Keller; Hanna M Seidling
Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.
A Rother; B Tönshoff; E Vitt; N von Ahsen; Victor W Armstrong; K Budde; David Czock; Reinhard Feneberg; Petra Glander; Michael Oellerich; Lutz T Weber
Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Czock (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Heiko Billing; David Czock; Thomas Giese; Stefan Meuer; Claudia Sommerer; Martin Zeier; Burkhard Tönshoff
Increased cyclosporin a sensitivity in vivo in pediatric renal transplant recipients compared with adults.
Therapeutic drug monitoring 2012;34(5):554-60.
2012: David Czock; Frieder Keller; Hanna M Seidling
Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.
British journal of clinical pharmacology 2012;74(1):66-74.
2012: A Rother; B Tönshoff; E Vitt; N von Ahsen; Victor W Armstrong; K Budde; David Czock; Reinhard Feneberg; Petra Glander; Michael Oellerich; Lutz T Weber
Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid.
European journal of clinical pharmacology 2012;68(6):913-22.
2011: Claudia Sommerer; Martin Zeier; David Czock; Stefan Meuer; Paul Schnitzler; Thomas Giese
Pharmacodynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremia.
Therapeutic drug monitoring 2011;33(4):373-9.
2011: Arwa Hassan; Jürgen Burhenne; Klaus-Dieter Riedel; Johanna Weiss; Gerd Mikus; Walter E Haefeli; David Czock
Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.
Therapeutic drug monitoring 2011;33(1):86-93.
2011: David Czock; Frieder Keller
[Drug-drug interactions and nephrotoxicity].
Therapeutische Umschau. Revue thérapeutique 2011;68(1):11-8.
2010: Bertram Hartmann; David Czock; Frieder Keller
Drug therapy in patients with chronic renal failure.
Deutsches Ärzteblatt international 2010;107(37):647-55; quiz 655-6.
2010: Sebastian Maus; Caecilia Holch; David Czock; Florian Thalhammer; Frieder Keller; Bertram Hartmann
[Questionnaire surveying nephrologists on drug dose adjustment in patients with impaired kidney function].
Wiener klinische Wochenschrift 2010;122(15-16):479-85.
2010: Verena Hafner; David Czock; Jürgen Burhenne; Klaus-Dieter Riedel; Jürgen Bommer; Gerd Mikus; Christoph Machleidt; T Weinreich; Walter E Haefeli
Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration.
Antimicrobial agents and chemotherapy 2010;54(6):2596-602.
2010: V Hafner; B Grün; C Markert; David Czock; Gerd Mikus; Walter E Haefeli
[Drug interactions].
Der Internist 2010;51(3):359-69; quiz 370.
2010: C Aymanns; Frieder Keller; Sebastian Maus; Bertram Hartmann; David Czock
Review on pharmacokinetics and pharmacodynamics and the aging kidney.
Clinical journal of the American Society of Nephrology : CJASN 2010;5(2):314-27.
2009: David Czock; Frieder Keller; Jörn Hameister; Birgit Tiefenbach; Steffen Mitzner
Levomethadone is poorly removed by the molecular adsorbents recirculating system.
Journal of clinical psychopharmacology 2009;29(6):622-4.
2009: Frieder Keller; Bertram Hartmann; David Czock
Explicit solution of integrated 1 - exp equation for predicting accumulation and decline of concentrations for drugs obeying nonlinear saturation kinetics.
Therapeutic drug monitoring 2009;31(6):783-5.
2009: David Czock; Thilo Bertsche; Walter E Haefeli
Drug dose adjustments in patients with renal impairment.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2009;54(5):983-4; author reply 985-6.
2009: Thilo Bertsche; Martina Fleischer; Johannes Pfaff; Jens Encke; David Czock; Walter E Haefeli
Pro-active provision of drug information as a technique to address overdosing in intensive-care patients with renal insufficiency.
European journal of clinical pharmacology 2009;65(8):823-9.
2009: David Czock; Christoph Markert; Bertram Hartman; Frieder Keller
Pharmacokinetics and pharmacodynamics of antimicrobial drugs.
Expert opinion on drug metabolism & toxicology 2009;5(5):475-87.
2009: David Czock; Franz Maximilian Rasche; Benjamin Boesler; Maria Shipkova; Frieder Keller
Irinotecan in cancer patients with end-stage renal failure.
The Annals of pharmacotherapy 2009;43(2):363-9.
2009: Frieder Keller; Bertram Hartmann; David Czock
Mean residence time as estimated from cropped and truncated moments.
Arzneimittel-Forschung 2009;59(7):377-81.
2007: David Czock; Frieder Keller
Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects.
Journal of pharmacokinetics and pharmacodynamics 2007;34(6):727-51.
2007: David Czock; Franz Maximilian Rasche; Alexander Carius; Petra Glander; Klemens Budde; Steffen Bauer; Frieder Keller; Lutz Von Müller
Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis.
Journal of clinical pharmacology 2007;47(7):850-9.
2007: Franz Maximilian Rasche; Frieder Keller; G Kunze; B Boesler; David Czock
Single daily dose of cyclosporine in patients with primary glomerulonephritis and nephrotic syndrome.
Clinical nephrology 2007;67(5):285-92.
2007: Franz Maximilian Rasche; Frieder Keller; Lutz Von Müller; David Czock; Philipp Lepper
Sequential immunosuppressive therapy in progressive IgA nephropathy.
Contributions to nephrology 2007;157():109-13.
2006: David Czock; Cordula Hüsig-Linde; Anita Langhoff; Timo Schöpke; Carsten Hafer; Kirsten de Groot; Stefanie Swoboda; Ernst Kuse; Hermann Haller; Danilo Fliser; Frieder Keller; Jan T Kielstein
Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis.
Clinical journal of the American Society of Nephrology : CJASN 2006;1(6):1263-8.
2006: David Czock
Pharmacodynamic dose adjustment in renal failure: importance of the Hill coefficient.
International journal of clinical pharmacology and therapeutics 2006;44(10):474-7.
2006: Franz Maximilian Rasche; Frieder Keller; Philipp Lepper; C Aymanns; Wolfram Karges; L-C Sailer; L von Müller; David Czock
High-dose intravenous immunoglobulin pulse therapy in patients with progressive immunoglobulin A nephropathy: a long-term follow-up.
Clinical and experimental immunology 2006;146(1):47-53.
2006: Franz Maximilian Rasche; Frieder Keller; Lutz Von Müller; Leif-Konradin Sailer; Wolfram Karges; David Czock
Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephropathy.
Journal of nephrology 2006;19(4):465-72.
2006: Jan T Kielstein; David Czock; Timo Schöpke; Carsten Hafer; Stefanie M Bode-Böger; Ernst Kuse; Frieder Keller; Danilo Fliser
Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis.
Critical care medicine 2006;34(1):51-6.
2005: David Czock; U Häussler; C Aymanns; Frieder Keller
[Nephrotoxic drugs].
Deutsche medizinische Wochenschrift (1946) 2005;130(45):2579-84; quiz 2585-6.
2005: Franz Maximilian Rasche; Frieder Keller; David Czock
[Chemotherapy in patients with renal failure, dialysis and after transplantation].
Deutsche medizinische Wochenschrift (1946) 2005;130(36):2043-6.
2005: Jan T Kielstein; Michael Stadler; David Czock; Frieder Keller; Bernd Hertenstein; Jörg Radermacher
Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure.
European journal of haematology 2005;74(6):533-4.
2005: Benjamin Boesler; David Czock; Frieder Keller; Martin Griesshammer; Thomas Seufferlein; Wolfram Karges; Franz Maximilian Rasche
Clinical course of haemodialysis patients with malignancies and dose-adjusted chemotherapy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2005;20(6):1187-91.
2005: David Czock; Franz Maximilian Rasche
Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval?
European journal of medical research 2005;10(4):145-8.
2005: David Czock; Frieder Keller; Mette Heringa; Franz Maximilian Rasche
Raloxifene pharmacokinetics in males with normal and impaired renal function.
British journal of clinical pharmacology 2005;59(4):479-82.
2005: David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Clinical pharmacokinetics 2005;44(1):61-98.
2004: Franz Maximilian Rasche; Leif-Conradin Sailer; David Czock; Frieder Keller
Tonsillectomy, high dose immunoglobulins, and cyclophosphamide in progressive IgA-nephropathy.
Acta oto-laryngologica. Supplementum 2004;(555):32-7.
2004: Franz Maximilian Rasche; Boris Uhel; Detlev H Krüger; Wolfram Karges; David Czock; Walter Hampl; Frieder Keller; Helga Meisel; Lutz Von Müller
Thrombocytopenia and acute renal failure in Puumala hantavirus infections.
Emerging infectious diseases 2004;10(8):1420-5.
2004: David Czock; Franz Maximilian Rasche
New AUC-based method to estimate drug fraction removed by hemodialysis.
Kidney & blood pressure research 2004;27(3):172-6.
2003: David Czock; U Aisenpreis; Franz Maximilian Rasche; P M Jehle
Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus.
International journal of clinical pharmacology and therapeutics 2003;41(10):492-7.
2003: Franz Maximilian Rasche; Christoph Hubert Klotz; David Czock; Wolfram Karges; Rainer Muche; Peter M Jehle; Andreas Mertz; Frieder Keller
Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy.
Nephron. Clinical practice 2003;93(4):c131-6.
2002: David Czock; Cornelia Scholle; Franz Maximilian Rasche; Dieter Schaarschmidt; Frieder Keller
Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
Clinical pharmacology and therapeutics 2002;72(2):142-50.
2002: A Uhl; David Czock; B-O Boehm; D Zellner; Andreas Mertz; Frieder Keller
Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions.
Journal of clinical pharmacy and therapeutics 2002;27(4):281-7.
2002: Frieder Keller; M Giehl; David Czock; D Zellner
PK-PD curve-fitting problems with the Hill equation? Try one of the 1-exp functions derived from Hodgkin, Douglas or Gompertz.
International journal of clinical pharmacology and therapeutics 2002;40(1):23-9.
2001: F Ernst; S Hetzel; Sylvia Stracke; David Czock; G Vargas; Manfred P Lutz; Frieder Keller; Peter M Jehle
Renal proximal tubular cell growth and differentiation are differentially modulated by renotropic growth factors and tyrosine kinase inhibitors.
European journal of clinical investigation 2001;31(12):1029-39.
2000: David Czock; M Giehl; Frieder Keller
A concept for pharmacokinetic-pharmacodynamic dosage adjustment in renal impairment: the case of aminoglycosides.
Clinical pharmacokinetics 2000;38(4):367-75.
1999: Frieder Keller; J Böhler; David Czock; D Zellner; Andreas Mertz
Individualized drug dosage in patients treated with continuous hemofiltration.
Kidney international. Supplement 1999;(72):S29-31.
1999: Frieder Keller; David Czock
Pharmacodynamic half-life and effect-time course in renal impairment.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1999;14 Suppl 4():6-8.
1999: David Czock; Frieder Keller
The area under the effect-time curve as a target parameter for dosage adaptation in renal insufficiency.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1999;14 Suppl 4():4.
1998: Frieder Keller; David Czock
Pharmacokinetic studies in volunteers with renal impairment.
International journal of clinical pharmacology and therapeutics 1998;36(11):594-8.
1998: Frieder Keller; David Czock; D Zellner; M Giehl
Relationship between pharmacokinetic half-life and pharmacodynamic half-life in effect-time modeling.
International journal of clinical pharmacology and therapeutics 1998;36(3):168-75.
1998: Frieder Keller; T Frankewitsch; D Zellner; S Simon; David Czock; M Giehl
Standardized structure and modular design of a pharmacokinetic database.
Computer methods and programs in biomedicine 1998;55(2):107-15.
1995: David Czock; M Giehl
Aminoglycoside pharmacokinetics and -dynamics: a nonlinear approach.
International journal of clinical pharmacology and therapeutics 1995;33(10):537-9.